Briquilimab
Phase 1/2Terminated 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Chronic Inducible Urticaria
Conditions
Chronic Inducible Urticaria
Trial Timeline
Mar 18, 2024 → Jul 31, 2025
NCT ID
NCT06353971About Briquilimab
Briquilimab is a phase 1/2 stage product being developed by Jasper Therapeutics for Chronic Inducible Urticaria. The current trial status is terminated. This product is registered under clinical trial identifier NCT06353971. Target conditions include Chronic Inducible Urticaria.
Hype Score Breakdown
Clinical
13
Activity
8
Company
2
Novelty
4
Community
3
Clinical Trials (4)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06736262 | Phase 2 | Active |
| NCT06592768 | Phase 1 | Terminated |
| NCT06353971 | Phase 1/2 | Terminated |
| NCT06162728 | Phase 1/2 | Active |
Competing Products
20 competing products in Chronic Inducible Urticaria